Department of Veterans Affairs Awarded a Contract to GLAXOSMITHKLINE, LLC for $15,647,512.50

Summary of Award

The JSON data from USAspending.gov details an awarded contract between the U.S. federal government and GlaxoSmithKline LLC (GSK), a leading pharmaceutical company. This contract concerns the procurement of the influenza vaccine for the 2024-2025 flu season, aligning with the government’s efforts to ensure public health and safety through seasonal vaccination programs.

### Contract Overview

**Contract Identification and Type:** The contract is designated by the unique award ID "CONT_IDV_36E79724D0005_3600" and is characterized as an "Indefinite Delivery/Requirements" contract. This type of contract allows the government to order goods or services from the contractor as requirements arise, but does not obligate the total amount upfront. The contracting vehicle used here is known as IDV_B_A, which refers to Indefinite Delivery Vehicles, Requirements type. **Period of Performance:** The timeline for this contract's performance starts on March 15, 2024, and concludes on March 14, 2025. It suggests a one-year comprehensive coverage of the flu season, allowing for the distribution and administration of vaccines as needed. **Financial Details:** Though the total obligation currently stands at $0, indicating no specific funds have been released yet, the contract’s ceiling is approximately $15.6 million. This allocation indicates the maximum potential expenditure for the delivery of services or products during the contract period. ### Recipient Details **GlaxoSmithKline LLC:** GSK, a global health care company headquartered in Durham, North Carolina, specializes in pharmaceutical and medical preparations. The company forms part of the pharmaceutical industry under the NAICS code 325412, which covers Pharmaceutical Preparation Manufacturing. It is recognized as a foreign-owned, yet U.S.-incorporated entity aiming to contribute significantly to addressing public health needs. **Business Categories:** GSK is categorized under several designations, such as Corporate Entity Not Tax Exempt, Foreign Owned, and Not Designated as a Small Business. These classifications may influence how the company engages with federal contracts, benefiting from its international expertise while adhering to domestic regulatory frameworks. ### Awarding and Funding Agencies **Department of Veterans Affairs (VA):** Both the awarding and the funding agency for this contract is the Department of Veterans Affairs, specifically through its office, NAC Pharmaceuticals (36E797). The VA’s involvement underscores its commitment to ensuring that veterans have access to critical medical supplies, such as the influenza vaccine. ### Contract Nature and Details **Competition and Solicitation:** The award process involved full and open competition, receiving three offers, highlighting a fair opportunity environment. The solicitation process was conducted through negotiated proposals or quotes, a typical procedure for contracts requiring detailed specifications and evaluations. **Pricing and Acquisition:** The type of contract pricing adopted is described as "Firm Fixed Price," indicating a set price arrangement which provides cost stability and predictability for both the government and GSK. This approach is common in situations where performance risks are deemed low and predictable. **Contract Scope and Services:** Under the PSC code 6505 related to Drugs and Biologicals, the contract primarily focuses on manufacturing and supplying influenza vaccines. This ensures alignment with the NAICS hierarchy that categorizes the work under Pharmaceutical and Medicine Manufacturing. ### Summary of Transactions and Future Implications Notably, there are no transactions recorded in the dataset at this time. This absence may highlight the preliminary nature of the documented contract stage, emphasizing the importance of monitoring subsequent financial activities related to this agreement as they become available. The contract delineates an essential public health initiative supported by the federal government through structured agreements with a leading pharmaceutical firm. The collaboration anticipates a robust response to influenza outbreaks during the specified flu season, spearheaded by a company with established expertise in vaccine production. In addition, the strategic partnership with GSK, facilitated by the VA, underscores a broader policy directive aimed at safeguarding public health infrastructure through timely procurement and deployment of critical health solutions. By fostering this collaboration with GSK, the government aims to bolster its flu prevention initiatives, ensuring widespread vaccine availability and response readiness throughout the flu season. This contract exemplifies the federal government’s proactive measures in public health management, leveraging both domestic and international pharmaceutical capabilities to meet national healthcare needs efficiently. Furthermore, it showcases the administrative efficacy of seamless interagency collaboration in executing high-stakes contracts crucial for national health priorities.